fbpx

Revealed: The Secrets our Clients Used to Earn $3 Billion

Family Funds Investing in Innovative Biomedical Companies and Non-profits

Share it with your friends Like

Thanks! Share it with your friends!

Close

The family fund has emerged as an important new source of capital to propel bioscience innovation and commercialization. Using wealth accumulated for making big impact, family funds invest in small and emerging companies, and make venture philanthropy investment type donations to nonprofits doing important focused work.

Speakers:

Tom McKenzie is Senior Vice President, Membership of Cavendish Global and a principal with Capital Partners LLC, a private equity advisory firm. Tom has 30 years of experience in executive positions in diverse organizations, ranging from Global 500 companies to venture startups. His vast experience includes growing and managing successful sales and marketing teams, private equity management, investment strategy, and working in venture capital projects and companies. In addition to Cavendish Global, Tom serves as Principal at Capital Partners LLC, where he performs due diligence, analysis, acquisition/transaction negotiation, marketing, sales, operations, financial management assessment of private equity and venture capital projects and companies. His career has included Principal positions at SkillMeasure, Global Novations, Behavioral Technology – Executive Assessment and Selection Firms as well as starting his career at FedEx. Tom holds a degree in Business Administration, with a focus in marketing and finance from the University of Memphis

Peter Harris is a Vice President & Managing Director at Axel Johnson, Inc. where he is involved with cultivating and evaluating new investment opportunities and providing strategic and operational support to existing portfolio companies. His areas of specific focus include industrial automation and advanced manufacturing, medical devices, life science and healthcare services, and in vitro diagnostics and analytical instrumentation. Prior to joining Axel Johnson, he was the CEO of Cadence, Inc. – a high technology medical device manufacturing and engineering firm enabling medical companies to bring better devices to market faster. Cadence has grown from an $8 million, 85% industrial products company to a $55 million 80% medical device and diagnostic products company. Peter has held the Cadence Chairman position since 2012. A persuasive public speaker, he regularly participates in community and industry events as a content provider. He also teaches at the University of Virginia’s Darden School of Business in the areas of leadership and change management. Undergraduate focus in mathematics and Mandarin. MBA from UVA. Dangerously rusty in Mandarin, but can still do rudimentary arithmetic as long as a calculator is handy.

Paul Romness serves as Senior Advisor to McKenna & Associates; specifically involved in the Life Sciences and other issue advocacy campaigns. McKenna & Associates is a strategic consulting firm specializing in management and fundraising. As a trusted advisor to our clients, they maximize your efforts with their extensive network of relationships and drive to unite the best ideas and initiatives with the most effective decision makers. Prior to joining McKenna & Associates, Mr. Romness started PR Strategies, LLC strategic consulting, focused on campaign and coalition development, execution and management. Prior to that, Mr. Romness was Vice President of Government Affairs and Public Policy (GAPP) for Boehringer Ingelheim, the largest privately held bio-pharmaceutical company in the world. His responsibilities included executing plans at the federal and state levels through the development of regulation, legislation and policy. He also led the management of the Boehringer Ingelheim Corporation Political Action Committee (BICPAC). His experience includes over twenty-five years in the bio-pharmaceutical industry, including Amgen and Johnson & Johnson, where his responsibilities included tracking and analyzing state legislation, policy and strategy development, as well as implementing strategies to advance the access of medicines to patients. Mr. Romness earned a Masters of Health Policy from George Washington University Medical Center and a Bachelor of Science in Finance from The American University, both in Washington, D.C. where he resides.

Comments

Write a comment